Leukemic Relapse
Showing 1 - 25 of 4,003
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in
Not yet recruiting
- Acute Myeloid Leukemia
- Genetic Predisposition to Disease
- Collection of blood sample of bone marrow (cohort 1)
- Collection of blood sample of bone marrow (cohort 2 and 3)
- (no location specified)
Mar 6, 2023
Chronic Myeloid Leukemia Trial in France (biological samples)
Completed
- Chronic Myeloid Leukemia
- biological samples
-
Belfort, France
- +3 more
May 31, 2022
Leukemia Trial (90-Yttrium-labelled anti-CD66 mAb)
Not yet recruiting
- Leukemia
- 90-Yttrium-labelled anti-CD66 monoclonal antibody
- (no location specified)
Aug 16, 2022
AML Trial in Berne (Image-based ex-vivo drug screening platform (pharmacoscopy))
Recruiting
- AML
- Image-based ex-vivo drug screening platform (pharmacoscopy)
-
Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
Feb 8, 2023
AML/MDS Trial in Copenhagen (iDLI)
Recruiting
- AML/MDS
- iDLI
-
Copenhagen, DenmarkCopenhagen University Hospital, Rigshospitalet
Jan 13, 2023
Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome Trial in Australia, Netherlands,
Recruiting
- Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome
-
Duarte, California
- +12 more
Jan 4, 2023
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding
Completed
- Leukemia, Acute
- (no location specified)
Jul 23, 2023
Relapsed/Refractory Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Leukemia Trial in France
Recruiting
- Relapsed/Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
-
Amiens, France
- +30 more
Apr 14, 2023
Hematologic Malignancy, Myeloid Malignancy Trial in Memphis (Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG))
Recruiting
- Hematologic Malignancy
- Myeloid Malignancy
- Ruxolitinib
- +10 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Nov 7, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytokine-Induced Memory-like Natural Killer Cells
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 22, 2023
Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)
Not yet recruiting
- Myeloid Malignancy
- Acute Myeloid Leukemia
-
Cleveland, OhioUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children Trial in Tours (Biological sampling in patients, Biological sampling
Not yet recruiting
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia in Children
- Biological sampling in patients
- Biological sampling in control patients
-
Tours, France
- +2 more
Mar 17, 2023
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, MDS Trial in Worldwide (Allogeneic Stem Cell
Recruiting
- Acute Myeloid Leukemia in Remission
- +2 more
- Allogeneic Stem Cell Transplantation
-
Graz, Austria
- +23 more
Oct 3, 2021
Acute Myelogenous Leukemia Trial in Australia, Canada, United States (Decitabine, Vorinostat, Filgrastim (G-CSF))
Completed
- Acute Myelogenous Leukemia
- Decitabine
- +4 more
-
Los Angeles, California
- +32 more
Jun 22, 2022
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)
Not yet recruiting
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia
- Venetoclax
- +16 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 23, 2022
Acute Myeloid Leukemia Trial in Ann Arbor (peg-IFN-a, Hematopoietic Cell Transplant (HCT), Tacrolimus)
Completed
- Acute Myeloid Leukemia
- peg-IFN-α
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Oct 1, 2021
Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma Trial (3D189)
Recruiting
- Acute Leukemia
- +3 more
- 3D189
-
Guangzhou, Guangdong, China
- +3 more
Jan 2, 2023
CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)
Not yet recruiting
- CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
- +3 more
- (no location specified)
Nov 14, 2022
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022
Acute Leukemia, in Relapse, Acute Leukemia Refractory Trial in Suzhou (CVA regimen bridging to HSCT)
Recruiting
- Acute Leukemia, in Relapse
- Acute Leukemia Refractory
- CVA regimen bridging to HSCT
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Jan 4, 2022
MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
- low dose 5'-azacitidine
-
Basking Ridge, New Jersey
- +6 more
Dec 1, 2022
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- +7 more
- Anti-CD123 ADC IMGN632
- +7 more
- (no location specified)
Dec 28, 2022
Novo Acute Myeloid Leukemia Trial in Spain (Mylotarg)
Completed
- Novo Acute Myeloid Leukemia
-
Badalona, Barcelona, Spain
- +5 more
Jan 26, 2021
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +3 more
- Laboratory Biomarker Analysis
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Jan 10, 2022